Avance Clinical, a global contract research organization focused on accelerating clinical development for biotech sponsors, announces the acquisition of LumaBridge, a specialized U.S.-based clinical CRO with deep expertise in oncology trials. This strategic acquisition expands Avance’s existing U.S. presence and marks a significant milestone in accelerating the company’s growth in oncology, the largest and fastest-growing therapeutic area in global R&D. Both organizations share a commitment to deliver high quality, innovative and efficient oncology clinical trials that accelerate the development of next-generation therapies to patients worldwide.
Read the full article: Avance Clinical Strengthens Global Oncology Offering with Acquisition of U.S.-Based LumaBridge //
Source: https://www.globenewswire.com/news-release/2026/01/07/3214396/0/en/Avance-Clinical-Strengthens-Global-Oncology-Offering-with-Acquisition-of-U-S-Based-LumaBridge-and-Establishes-New-Oncology-Center-of-Excellence.html